The VIH in its initials represents the death that there was a treacherous disease to treat. It is embarrassing, it has changed with the passage of years and some medicines have allowed it to be a treatable disease and can be controlled.
Daniela Osorio Rivera
Agencia Latina de Noticias Medicina y Salud Pública
Agreed with the press release of Medicine and Public Health, the president of the Association of Medical Practitioners of Puerto Rico Villamary Rosa assured that, since ten decades the drugs for the VIH have experimented cambios to increase patient life.
The specialist explained, “The VIH initially was a virus without treatment that would slow down the death of patients in order to provide effective treatment. Currently the virus is treatable, as well as some of the drugs that are being developed can be identified as a functional cure, which reduces or eliminates the viral reserves in the patient with VIH ”
Here you will find a record of the history of recently approved medicines, which are sometimes approved or have completed three stages of development.
Medicines recently approved
Doravirina (Pifeltro) approved in August 2018, is an NNRTI (Non-Nucleoside Reverse Transcriptase Inhibitor) this drug is of diary use, its dose is one day old and can be consumed without food.
Approved in April 2019, this drug is an integrated combination between Dolutegravir and NRTI.
Ibalizumab was approved in March 2018, it was the first monoclonal anticoagulant to treat positive patients of VIH
Medicines that he completed stage 3
Cabotegravir / RilpivirinaLA approved on April 29, 2019 by Viiv helseheidsorg, this medicine has been approved for approval, reports more than 90% of its prescription.
Cabotegravir is a second generation of inhibitors that have been developed in presentations, tables and injectables, the oral form is visualized to be used as injectables.
Fostemsavir- is an ancillary inhibitor. This medicine is active for all VIH subtypes.
Development phase 3 compilations
Leronlimab-EAB This drug has been unrolled for more than one decade at the moment and is currently undergoing approval for the potential that it has, too, has been portrayed as a drug in the cambio, once a patient has been depressed.
UB-421mAb is a monoclonal antibody with a high neutralizing spectrum for the patient.
These medicines mark a difference for the patients with VIH that I have in their care and have the greater possibility of getting rid of this disease.